KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Capital Expenditures (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Capital Expenditures data on record, last reported at $57.5 million in Q3 2025.

  • For Q3 2025, Capital Expenditures rose 10.79% year-over-year to $57.5 million; the TTM value through Sep 2025 reached $212.6 million, down 26.92%, while the annual FY2024 figure was $252.4 million, 0.24% changed from the prior year.
  • Capital Expenditures reached $57.5 million in Q3 2025 per EW's latest filing, up from $49.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $106.0 million in Q1 2021 and bottomed at $43.1 million in Q2 2022.
  • Average Capital Expenditures over 5 years is $64.0 million, with a median of $59.9 million recorded in 2022.
  • The widest YoY moves for Capital Expenditures: up 78.29% in 2024, down 43.6% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $69.3 million in 2021, then dropped by 0.58% to $68.9 million in 2022, then grew by 28.16% to $88.3 million in 2023, then crashed by 43.6% to $49.8 million in 2024, then rose by 15.46% to $57.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $57.5 million in Q3 2025, $49.3 million in Q2 2025, and $56.0 million in Q1 2025.